Comparative effects of Interferon-Consensus 1, Interferon-α2a, and Interferon-β1b on HLA expression and lymphoproliferation: A preclinical model for treatment of multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 16, Issue 3, 1996, Pages 195-200

  Dhib Jalbut, Suhayl ^a,b,d   Jiang, Hong ^a   Xia, Qian ^a   Blatt, Lawrence ^c   Johnson, Kenneth P ^a   Hilt, Dana ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BETA1 INTERFERON;

ARTICLE; GENE EXPRESSION REGULATION; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ADJUVANTS, IMMUNOLOGIC; CELL LINE; CONCANAVALIN A; DRUG EVALUATION, PRECLINICAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON ALFA-2A; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; LYMPHOPROLIFERATIVE DISORDERS; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 0029881552     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.195     Document Type: Review

References (14)

1. WEINSTOCK-GUTTMAN, B., RANSOHOFF, R.M., KINKEL, R.P., and RUDICK, R.A. (1995). The interferons: biological effects, mechanisms of action and use in multiple sclerosis. Ann. Neurol. 37, 7-15.
2. KLEIN, M.L., BARTLEY, T.D., LAI, P-H., and LU, H.S. (1988). Structural characterization of recombinant consensus interferon-α. J. Chromatogr. 45, 205-215.
3. OZES, O.N., REITER, Z., KLEIN, S., BLATT, L.M., and TAYLOR, M.W. (1992). A comparison of interferon-Con 1 with natural recombinant interferon-α. Antiviral, antiproliferative, and natural killer-inducing activities. J. Interferon Res. 12, 55-59.
4. IFN-β Multiple Sclerosis Study Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43, 655-661.
5. PATY, D.W., LI, D.K.B., UBC MS/MRI Study Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 662-667.
6. PANITCH, H.S., HIRSCH, R.L., SCHINDLER, J., and JOHNSON, K.P. (1987). Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activities of the immune system. Neurology 37, 1097-1102.
7. ARANSON, B.G.W. (1993). Interferon beta in multiple sclerosis. Neurology 43, 641-643.
8. JIANG, H., MILO, R., SWOVELAND, P., JOHNSON, K.P., PANITCH, H., and DHIB-JALBUT, S. (1995). Interferon β-1b reduced interferon γ-induced antigen-presenting capacity of human glial and B cells. J. Immunol. 61, 17-25.
9. DHIB-JALBUT, S., and COWAN, E.P. (1993). Direct evidence that interferon-β mediates enhanced HLA-class I expression in measles virus-infected cells. J. Immunol. 151, 6248-6258.
10. WINTER, C.C., CARRENO, B.M., TURNER, R.V., KEONIG, S., and BIDDISON, W.E. (1991). The 45 pocket of HLA-A2.1 plays a role in presentation of influenza virus matrix peptide and alloantigens. J. Immunol. 146, 3508-3512.
11. DHIB-JALBUT, S., MCFARLIN, D.E., and MCFARLAND, H.F. (1989). Measles virus-polypeptide specificity of the cytotoxic T-lymphocyte response in multiple sclerosis. J. Neuroimmunol. 21, 205-212.
12. LING, P.D., WARREN, M.K., and VOGEL, S.N. (1985). Antagonistic effect of interferon beta on the interferon gamma induced expression of Ia antigen in murine macrophages. J. Immunol. 135, 1857-1863.
13. INABA, K., KITAURA, M., KATO, T., WATANABE, Y., KAWADE, Y., and MURAMATSU, S. (1986). Contrasting effects of alpha/beta and gamma-interferons on expression of macrophage Ia antigens. J. Exp. Med. 163, 1030-1035.
14. GOLDSTEIN, D., SIELAFF, K.M., STORER, B.E., BROWN, R.R., DATTA, S.P., WITT, P.L., TEITELBAUM, A.P., SMALLEY, R.V., and BORDEN, E.C. (1989). Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. J. Natl. Cancer Inst. 81, 1061-1068.